A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier
Open Access
- 25 June 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (6), e2469
- https://doi.org/10.1371/journal.pone.0002469
Abstract
Therapeutic intervention in many neurological diseases is thwarted by the physical obstacle formed by the blood-brain barrier (BBB) that excludes most drugs from entering the brain from the blood. Thus, identifying efficacious modes of drug delivery to the brain remains a “holy grail” in molecular medicine and nanobiotechnology. Brain capillaries, that comprise the BBB, possess an endogenous receptor that ferries an iron-transport protein, termed p97 (melanotransferrin), across the BBB. Here, we explored the hypothesis that therapeutic drugs “piggybacked” as conjugates of p97 can be shuttled across the BBB for treatment of otherwise inoperable brain tumors. Human p97 was covalently linked with the chemotherapeutic agents paclitaxel (PTAX) or adriamycin (ADR) and following intravenous injection, measured their penetration into brain tissue and other organs using radiolabeled and fluorescent derivatives of the drugs. In order to establish efficacy of the conjugates, we used nude mouse models to assess p97-drug conjugate activity towards glioma and mammary tumors growing subcutaneously compared to those growing intracranially. Bolus-injected p97-drug conjugates and unconjugated p97 traversed brain capillary endothelium within a few minutes and accumulated to 1–2% of the injected by 24 hours. Brain delivery with p97-drug conjugates was quantitatively 10 fold higher than with free drug controls. Furthermore, both free-ADR and p97-ADR conjugates equally inhibited the subcutaneous growth of gliomas growing outside the brain. Evocatively, only p97-ADR conjugates significantly prolonged the survival of animals bearing intracranial gliomas or mammary tumors when compared to similar cumulated doses of free-ADR. This study provides the initial proof of concept for p97 as a carrier capable of shuttling therapeutic levels of drugs from the blood to the brain for the treatment of neurological disorders, including classes of resident and metastatic brain tumors. It may be prudent, therefore, to consider implementation of this novel delivery platform in various clinical settings for therapeutic intervention in acute and chronic neurological diseases.Keywords
This publication has 103 references indexed in Scilit:
- Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumorsBiomaterials, 2008
- Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude miceZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Blood–brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horsesJournal of Controlled Release, 2007
- Fusion Antibody for Alzheimer's Disease with Bidirectional Transport Across the Blood−Brain Barrier and Aβ Fibril DisaggregationBioconjugate Chemistry, 2007
- Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruptionProceedings of the National Academy of Sciences of the United States of America, 2006
- Adriamycin, 14-Hydroxydaunomycin, a new antitumor antibiotic fromS. peucetius var.caesiusBiotechnology & Bioengineering, 2000
- Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System LymphomaNeurosurgery, 2000
- Murine tumor necrosis factor alpha is transported from blood to brain in the mouseJournal of Neuroimmunology, 1993
- Clinical Pharmacokinetics of DoxorubicinClinical Pharmacokinetics, 1988
- Differentiation-dependent expression of proteins in brain endothelium during development of the blood-brain barrierDevelopmental Biology, 1986